Back to Search
DANIEL SPRIGGS, M.D.
M.D.
Family Medicine Physician
NPI: 1417963315IndividualAccepts Medicare
Specialties, Licenses & Credentials
Family Medicine PhysicianPrimary
Family Medicine
Code: 207Q00000X
00013749(AL)
CMS Specialties
PrimaryFAMILY PRACTICE
Education
HOWARD UNIVERSITY COLLEGE OF MEDICINE
Class of 1986
Research & Publications (20)
Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study.
PMID 17906207·J Clin Oncol·2007
3-trial
Optimal sequencing in the treatment of recurrent ovarian cancer.
PMID 13129495·Gynecol Oncol·2003
6-review
The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group study.
PMID 19156927·Cancer·2009
8-other
Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study.
PMID 19135708·Gynecol Oncol·2009
3-trial
CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group study.
PMID 19195045·Cancer·2009
6-review
A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer.
PMID 18554700·Gynecol Oncol·2008
3-trial
A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies.
PMID 18827039·Clin Trials·2008
4-observational
Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission.
PMID 18451240·Clin Cancer Res·2008
3-trial
A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors.
PMID 17364235·Invest New Drugs·2007
3-trial
Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials.
PMID 17614127·Gynecol Oncol·2007
4-observational
Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer.
PMID 17634545·Clin Cancer Res·2007
8-other
Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop.
PMID 17950384·Gynecol Oncol·2007
8-other
Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas.
PMID 17261851·J Clin Oncol·2007
3-trial
Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors.
PMID 17053987·Invest New Drugs·2007
3-trial
Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer.
PMID 17023034·Gynecol Oncol·2007
8-other
A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission.
PMID 17918264·Cancer·2007
3-trial
CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
PMID 16996584·Gynecol Oncol·2007
8-other
Population analysis of a 24-h paclitaxel infusion in advanced endometrial cancer: a gynaecological oncology group study.
PMID 16842379·Br J Clin Pharmacol·2006
3-trial
Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
PMID 17000686·Clin Cancer Res·2006
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 116 CARONDOLET CT W
MOBILE, AL 36608 - Phone
- (251) 709-9920
Quick Facts
- NPI
- 1417963315
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 40
- Publications
- 20
Are you this provider?
Claim Your Profile